共 50 条
Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
被引:8
|作者:
Ciftciler, Rafiye
[1
]
Ciftciler, Ali Erdinc
[2
]
Malkan, Umit Yavuz
[3
]
Haznedaroglu, Ibrahim C.
[1
]
机构:
[1] Hacettepe Univ, Dept Hematol, Fac Med, Med Sch, TR-06100 Ankara, Turkey
[2] Kizilcahamam State Hosp, Dept Gen Surg, Ankara, Turkey
[3] Diskapi Educ & Res Hosp, Dept Hematol, Ankara, Turkey
来源:
SAGE OPEN MEDICINE
|
2020年
/
8卷
关键词:
Ankaferd hemostat;
clinical hemorrhages;
infections;
wound healing;
cancer;
EFFICACY;
AGENT;
PATIENT;
APOPTOSIS;
MODEL;
TRIAL;
ABS;
D O I:
10.1177/2050312120907811
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects.
引用
收藏
页数:8
相关论文